The current ratio of 37.28 in 2026Q2 is exceptionally high, driven by the cash influx from the equity raise, which increased cash to $54.3M from $19.4M sequentially. This provides a substantial liquidity cushion, but the rapid escalation in R&D spending—up 54% quarter-over-quarter in 2026Q2—suggests the runway may be shorter than the ratio implies. Investors should monitor whether the burn rate continues to accelerate, as the current ratio could deteriorate quickly if clinical trial costs rise further.

With a D/E ratio of 0.00 and interest coverage metrics that are negative due to pre-revenue losses, Trevi's balance sheet is essentially unlevered. This suggests that the company is not exposed to refinancing or covenant risks, but it also means that all funding must come from equity issuance, which dilutes shareholders. The negative interest coverage ratios in 2024 (e.g., -11,398 in 2024Q4) are not meaningful in the traditional sense, as they reflect minimal interest expense relative to operating losses, but they underscore the company's dependence on equity capital.

The ROIC trend shows a narrowing of losses from -21.5% in 2024Q3 to -7.3% in 2026Q2, which appears positive, but this is largely due to the equity raise inflating the capital base rather than operational improvement. The 54% quarter-over-quarter increase in R&D spending in 2026Q2 indicates that the company is investing heavily in clinical trials, which may lead to a deterioration in ROIC if the spending does not translate into successful product development. The negative ROIC is expected for a pre-revenue biotech, but the magnitude of the loss relative to invested capital warrants close monitoring.

The absence of meaningful asset turnover ratios reflects the nature of a pre-revenue biotech, where the primary 'assets' are intangible clinical programs and cash. The working capital swings, such as the DPO of 8,108 days in 2026Q1, are artifacts of minimal payables and are not indicative of operational efficiency. The cash conversion cycle is not meaningful without revenue, so investors should focus on the burn rate relative to cash on hand, which is currently about three quarters of runway based on the 2026Q2 burn of $17.6M and cash of $54.3M.

Trevi's ROE of -7.2% is better than PRAX's -34.1% and IDYA's -16.5%, but this is partly due to the recent equity raise boosting equity. The P/B of 14.62 is elevated relative to IDYA (3.14) and ACAD (3.94), indicating that investors are paying a premium for Trevi's pipeline, likely reflecting optimism about its lead candidate. However, the lack of revenue and the escalating burn rate suggest that the company must deliver clinical milestones to justify this valuation, otherwise the multiple could compress.